mr. yaping li, mayor of suzhou visited alphamab oncology-凯发88

english 中文简体 中文繁体

mr. yaping li, mayor of suzhou visited alphamab oncology

janurary 22, 2020 15:26 eastern daylight time

on january 21, yaping li, mayor of suzhou and deputy secretary of the cpc suzhou municipal committee, and his delegation visited alphamab oncology to meet with dr. ting xu, the founder, chairman and ceo of the company and an awardee of china’s national key expert program.

dr. ting xu was rewarded mayor’s award for science and technology innovation and entrepreneurship in suzhou, and top ten talent award for innovation and entrepreneurship in jiangsu province. he returned to china in 2008 and founded alphamab oncology in suzhou industrial park (sip). the company has developed several innovative antibody and protein engineering platforms and has successfully developed more than 30 biosimilars candidates and 20 innovative biological drug candidates. its bi-specific antibody and protein engineering have clear differentiation and global competitiveness. dr. ting xu has led or participated in over 20 national and ministerial projects and has contributed to more than 100 patents and patent applications.

during the visit, mayor li had a cordial talk with dr. ting xu and conveyed his new year’s regards to dr. xu on behalf of the suzhou municipal party committee and government. after that, mayor li and his delegation visited the exhibition hall of alphamab oncology to further understand the company's history, technology, product pipeline and vision. mayor li congratulated alphamab oncology for its outstanding achievements since its founding, and encouraged the company to proactively rise up to the complex and changing international market environment,  insist on its strategic determination, adapt to the latest trend, pursue quality and excellence, and build its own brand. the company should act as a pioneer and leader of private enterprises in suzhou, taking innovation as the first driving force for development, focusing on independent research and development, and competing with the leading  global companies. mayor li hopes that alphamab oncology would further climb the peak of technology, cultivate more scientific and technological talents, and help suzhou's innovation and development.

dr. ting xu warmly welcome the officials from suzhou municipality and sip district, and thanked the municipal party committee, municipal government and the sip or their long-term help and support to alphamab oncology. alphamab oncology will adhere to its original aspiration, high-quality development, respond actively to “further opening-up", and contribute to the society with greater achievements.

accompanying members of this visit include xin lu, minister of the organization department of the suzhou municipal committee; wei zhou, secretary-general of the suzhou municipal government; yanyan chen, deputy director of veteran cadre bureau and secretary of the working committee of retired cadres of the suzhou municipal committee; lixin ding, deputy secretary of the sip party working committee and director of the sip management committee; xiaoming lin, member of the sip party working committee and deputy director of the sip management committee, and officials from sip organization department and foreign affairs office.

about alphamab oncology

alphamab oncology is a biopharmaceutical company focusing on the research and development, manufacturing and commercialization of biologics for oncology. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.

alphamab has fully integrated proprietary biologics platform in bi-specifics and protein engineering. its highly differentiated in-house pipeline consists of eight anti-cancer drug candidates, four of which have advanced into phase i – iii clinical development phases in china, us and japan.  

the company also has proprietary crib and cram platforms for bi-specifics and antibody mixtures, and state-of-the-art manufacturing capability designed and built to meet nmpa and eu/fda’s cgmp standards.

with multiple in-house proprietary platforms for innovative biopharmaceuticals, alphamab oncology has built a robust pipeline in oncology/immunology to benefit cancer patients around the world.

visit for more information.